Selective HDAC6 Inhibitor Compounds With Tailored Zinc Coordination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HDAC inhibitors face challenges in achieving selectivity for HDAC6 over other HDAC isoforms, leading to clinical toxicity and poor pharmacokinetic properties due to indiscriminate metal-binding groups, particularly the hydroxamic acid motif.
Innovation Solution
Development of compounds with specific metal-binding groups that selectively target HDAC6, avoiding the use of hydroxamic acid, to modulate its activity and treat diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hydroxamic acid metal-binding groups are used in HDAC inhibitors, then potency against HDAC enzymes is improved, but selectivity for HDAC6 over other isoforms deteriorates leading to off-target effects
Solution Approach 1:
The patent applies local quality by designing metal-binding groups with specific chemical characteristics tailored to HDAC6's unique zinc coordination environment. Instead of using generic hydroxamic acid groups that bind indiscriminately to zinc ions in all HDAC isoforms, the invention employs customized ligands (such as pyridine carboxylic acid derivatives or other selective chelators) that form stable complexes specifically with HDAC6's zinc ion through tailored coordination geometry and binding affinity, thereby achieving high potency while maintaining isoform selectivity and reducing off-target effects
Solution Approach 2:
The patent applies parameter changes by systematically modifying the chemical parameters of metal-binding groups to optimize selectivity. This includes adjusting pKa values, coordination geometry, binding constants, and molecular recognition features of the ligands to match HDAC6's specific active site characteristics. By tuning these chemical parameters, the inhibitors achieve differential binding affinity for HDAC6 versus other HDAC isoforms, enabling selective inhibition without the broad-spectrum toxicity associated with non-selective hydroxamic acid-based inhibitors
2Reliability
If tightly binding metal-binding groups are used, then potency is improved, but selectivity for target enzyme versus related metalloenzymes deteriorates
Solution Approach 1:
The patent applies local quality by designing metal-binding groups with specific chemical characteristics tailored to HDAC6's unique zinc coordination environment. Instead of using generic hydroxamic acid groups that bind indiscriminately to zinc ions in all HDAC isoforms, the invention employs customized ligands (such as pyridine carboxylic acid derivatives or other selective chelators) that form stable complexes specifically with HDAC6's zinc ion through tailored coordination geometry and binding affinity, thereby achieving high potency while maintaining isoform selectivity and reducing off-target effects
Solution Approach 2:
The patent applies parameter changes by systematically modifying the chemical parameters of metal-binding groups to optimize selectivity. This includes adjusting pKa values, coordination geometry, binding constants, and molecular recognition features of the ligands to match HDAC6's specific active site characteristics. By tuning these chemical parameters, the inhibitors achieve differential binding affinity for HDAC6 versus other HDAC isoforms, enabling selective inhibition without the broad-spectrum toxicity associated with non-selective hydroxamic acid-based inhibitors
3Reliability
If hydroxamic acid groups are used to inhibit metalloenzymes, then enzymatic activity is effectively suppressed, but clinical toxicity increases due to indiscriminate binding
Solution Approach 1:
The patent applies local quality by designing metal-binding groups with specific chemical characteristics tailored to HDAC6's unique zinc coordination environment. Instead of using generic hydroxamic acid groups that bind indiscriminately to zinc ions in all HDAC isoforms, the invention employs customized ligands (such as pyridine carboxylic acid derivatives or other selective chelators) that form stable complexes specifically with HDAC6's zinc ion through tailored coordination geometry and binding affinity, thereby achieving high potency while maintaining isoform selectivity and reducing off-target effects
Solution Approach 2:
The patent applies parameter changes by systematically modifying the chemical parameters of metal-binding groups to optimize selectivity. This includes adjusting pKa values, coordination geometry, binding constants, and molecular recognition features of the ligands to match HDAC6's specific active site characteristics. By tuning these chemical parameters, the inhibitors achieve differential binding affinity for HDAC6 versus other HDAC isoforms, enabling selective inhibition without the broad-spectrum toxicity associated with non-selective hydroxamic acid-based inhibitors
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds provide improved selectivity and pharmacokinetic profiles for HDAC6 inhibition, reducing off-target effects and potential toxicity, offering therapeutic potential in oncology, neurology, and immunology.
Implementation Method 1
The compounds can comprise a metal-binding group that is capable of binding to a metal ion
Data Source
AI summary
Provided are compounds having HDAC6 modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by HDAC6.